iShares U.S. Pharmaceuticals ETF (IHE)
|Ex-Dividend Date||Jun 9, 2022|
|Day's Range||188.34 - 189.75|
|Inception Date||May 1, 2006|
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified.
Top 10 Holdings76.95% of assets
|Johnson & Johnson||JNJ||21.53%|
|Merck & Co.||MRK||4.65%|
|Eli Lilly and Company||LLY||4.60%|
|Bristol-Myers Squibb Company||BMY||4.50%|
|Jun 9, 2022||$0.71711||Jun 15, 2022|
|Mar 24, 2022||$0.79357||Mar 30, 2022|
|Dec 13, 2021||$0.7898||Dec 17, 2021|
|Sep 24, 2021||$0.832||Sep 30, 2021|
|Jun 10, 2021||$0.72063||Jun 16, 2021|
|Mar 25, 2021||$0.63484||Mar 31, 2021|
Johnson & Johnson continued its long streak of earnings beat. It outpaced revenue estimates as well but cut its full-year guidance on a strong dollar.
Sector ETF report for IHE
BIL and IHE both ETFs had traded in an outsized volume yesterday.
These ETFs can balance stability and long-term growth.
Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.
Just when it seemed like the Omicron coronavirus variant might overshadow the traditional Santa Claus Rally, and stocks might be due for a deeper sell-off, equities gained momentum, bouncing for a secon...
Travel and leisure stocks and ETFs are making major moves on Friday, following a better-than-expected October jobs report, and a fresh development in the coronavirus battle boosting enthusiasm for the ...
The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.
Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.
Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administration r...
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.